Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

被引：2
|
作者：
Kutsch, Nadine [1 ,2 ,3 ]
Ligtvoet, Rudy [1 ,2 ,3 ]
Robrecht, Sandra [1 ,2 ,3 ]
Linde, Hartmut
Illmer, Thomas
Doerfel, Steffen [4 ]
Lipke, Joerg
Aldaoud, Ali
Schlag, Rudolf
Dengler, Jolanta
Al-Sawaf, Othman [1 ,2 ,3 ]
Langerbeins, Petra [1 ,2 ,3 ]
Cramer, Paula [1 ,2 ,3 ]
Eichhorst, Barbara F. [5 ]
Hallek, Michael [1 ,2 ]
Fischer, Kirsten [1 ,2 ,3 ]
Fink, Anna Maria [1 ,2 ,3 ]
机构：
[1] Univ Cologne, Fac Med, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[3] Univ Cologne, German CLL Study Grp, Cologne, Germany
[4] Ctr Oncol Dresden, Freiberg, Meissen, Germany
[5] Univ Cologne, Cologne, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185741
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Targeted agents in chronic lymphocytic leukemia (CLL): data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
    Kutsch, Nadine
    Ligtvoet, Rudy
    Robrecht, Sandra
    Linde, Hartmut
    Illmer, Thomas
    Doerfel, Steffen
    Lipke, Jorg
    Aldaout, Ali
    Schlag, Rudolf
    Dengler, Jolanta
    Al-Sawaf, Othman
    Langerbeins, Petra
    Cramer, Paula
    Eichhorst, Barbara
    Hallek, Michael
    Fischer, Kirsten
    Fink, Anna
    LEUKEMIA & LYMPHOMA, 2023, 64 : S125 - S126
  • [2] Second primary malignancies (SPM) in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL Study Group (GCLLSG)
    Fuerstenau, M.
    Stumpf, T.
    Fink, A. -M.
    Robrecht, S.
    Bahlo, J.
    Maurer, C.
    Linde, H.
    Jacobasch, L.
    Doerfel, S.
    Lipke, J.
    Aldaoud, A.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 19 - 19
  • [3] Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Von Tresckow, J.
    Lange, E.
    Kiehl, M.
    Dreyling, M.
    Ritgen, M.
    Duerig, J.
    Tausch, E.
    Schneider, C.
    Stilgenbauer, S.
    Wendtner, C. M.
    Fischer, K.
    Goede, V
    Hallek, M.
    Eichhorst, B.
    LEUKEMIA, 2021, 35 (01) : 169 - 176
  • [4] Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    O. Al-Sawaf
    S. Robrecht
    J. Bahlo
    A. M. Fink
    P. Cramer
    J. v Tresckow
    E. Lange
    M. Kiehl
    M. Dreyling
    M. Ritgen
    J. Dürig
    E. Tausch
    C. Schneider
    S. Stilgenbauer
    C. M. Wendtner
    K. Fischer
    M. Goede
    B. Hallek
    Leukemia, 2021, 35 : 169 - 176
  • [5] First-line treatment and outcome in patients with chronic lymphocytic leukemia (CLL) according to age: a report of the German CLL Study Group (GCLLSG) registry
    Maurer, C.
    Fink, A. M.
    Robrecht, S.
    Bahlo, J.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 170 - 171
  • [6] Treatment of chronic lymphocytic Leukemia in over 80 Years: Experience of the German CLL Study Group (GCLLSG)
    Goede, V.
    Engelke, A.
    Busch, R.
    Hallek, M.
    INTERNIST, 2013, 54 : 127 - 127
  • [7] Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Robrecht, Sandra
    Bahlo, Jasmin
    Al-Sawaf, Othman
    Langerbeins, Petra
    Heinz, Werner
    Vehling-Kaiser, Ursula
    Durig, Jan
    Tausch, Eugen
    Hensel, Manfred
    Fink, Anna-Maria
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara F.
    Hallek, Michael J.
    BLOOD, 2017, 130
  • [8] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2022, 140 : 9879 - 9881
  • [9] Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Von Tresckow, Julia
    Fink, Anna-Maria
    Braun, Gracia
    Robrecht, Sandra
    Zhang, Can
    Tausch, Eugen
    Mueller, Lothar
    Knauf, Wolfgang
    Al-Sawaf, Othman
    Pelzer, Benedikt
    Langerbeins, Petra
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2020, 136
  • [10] Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fink, Anna-Maria
    Busch, Raymonde
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Pflug, Natali
    Schubert, Friederike
    Doehner, Hartmut
    Rieger, Michael
    Kneba, Michael
    Mayer, Jiri
    Hallek, Michael
    Fischer, Kirsten
    BLOOD, 2011, 118 (21) : 1235 - 1235
12345